Brain scans may predict who will respond to psychosis treatment

NCT ID NCT02670447

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether MRI brain scans can help predict which patients having their first psychotic episode will not respond to standard treatment. Researchers will scan 80 people aged 18-35 with schizophrenia or related disorders who have never taken antipsychotic medication. The goal is to see if certain brain markers can identify non-responders by the third month of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRI (Magnetic Resonance Imaging)
What this could lead to: If successful, this could help doctors identify non-responding patients earlier, allowing for faster adjustments in treatment.
What could go wrong: This is a small, early-stage study (80 participants) focused on observation, not treatment. The MRI markers may not prove reliable enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOAFFECTIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizoaffective disorder schizophrenia schizophreniform disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Chu Clermont-Ferrand
NOT_YET_RECRUITING

Clermont-Ferrand, 63003, France
Chu Grenoble
NOT_YET_RECRUITING

Grenoble, 38000, France
Chu Le Vinatier
NOT_YET_RECRUITING

Bron, 69500, France
Chu Saint Etienne
RECRUITING

Saint-Etienne, 42100, France
HÔPITAL Edouard Herriot
NOT_YET_RECRUITING

Lyon, 69003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.